uniQure, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on the stock and has a $70.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Patrick Trucchio has given his Buy rating due to a combination of factors, primarily focusing on the promising initial data from uniQure’s AMT-191 gene therapy for Fabry disease. The data presented at the International Congress of Inborn Errors of Metabolism showed significant enzyme activity increases and the potential for patients to discontinue enzyme replacement therapy, all while maintaining a manageable safety profile. This positions AMT-191 as a potentially best-in-class treatment option for Fabry disease, which currently has limited alternatives beyond enzyme replacement therapy.
Additionally, the ongoing advancement of uniQure’s AMT-130 for Huntington’s disease, with a Biologics License Application expected in early 2026, further supports the Buy rating. The valuation of uniQure is based on a discounted cash flow and sum-of-the-parts analysis, projecting a firm value of approximately $3.8 billion and a price target of $70. Despite the inherent risks associated with clinical development and commercialization, the potential for significant revenue growth from uniQure’s gene therapy platform in the future underpins the positive outlook.
Trucchio covers the Healthcare sector, focusing on stocks such as GH Research, Arrowhead Pharmaceuticals, and Oncolytics Biotech. According to TipRanks, Trucchio has an average return of 11.0% and a 43.71% success rate on recommended stocks.